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Cardiovascular Risk Factors Prior to the Development 
of Non-Insulin-Dependent Diabetes Mellitus in 
Persons with Impaired Glucose Tolerance: 
The Hoorn Study 
G. Nijpels,‘~’ C. Popp-Snijders,2 P. J. Kostense,3 L. M. BouteT,‘a3 and R. J. HeineJa2 
'INSTITUTE FOR RESEARCH IN EXTRAMURAL MEDICINE, ‘RESEARCH INSTITUTE 
FOR ENDOCRINOLOGY, REPRODUCTION, AND METABOLISM, AND ‘DEPARTMENT OF 
EPIDEMIOLOGY AND BIOSTATISTICS, VRIJE UNIVERSITEIT 1081 BT AMSTERDAM, THE NETHERLANDS 
ABSTRACT. The aim of the study was to analyze cardiovascular risk factors as predictors for developing non- 
insulin-dependent diabetes mellitus (NIDDM) in people with impaired glucose tolerance. A cross-sectional sur- 
vey of glucose tolerance was conducted in people, aged 50-74, w h o were randomly selected from the registry 
of the middle-sized town Hoorn (The Netherlands). Based on the mean values of two oral glucose tolerance 
tests, people were classified in glucose tolerance categories according to the WHO criteria. The mean follow- 
LIP> time was 36 months (range 13-55 months). The cumulative incidence of NIDDM was 34% (95% CI 16.9% 
45.1). In multiple logistic regression analysis, cardiovascular risk factors at baseline did not predict the conversion 
from impaired glucose tolerance to NIDDM, in contrast with the two-hour plasma glucose level (odds ratio 
3.56, p < 0.001) and the fasting proinsulin level, as one of the determinants of beta-cell dysfunction (Odds 
ratio 2.1, p < 0.05). The baseline HDL- h 1 ‘t c o eb ero 1 1 eve , one of the components of the insulin resistance syn- 1 
drome, was associated with the conversion from impaired glucose tolerance to normal glucose tolerance (Odds 
ratio 1.58, p < 0.05). The results of our study seem to support the hypothesis that conversion from impaired 
glucose tolerance to normal glucose tolerance depends on insulin resistance and the development of NIDDM 
from impaired glucose tolerance depends on beta-cell dysfunction. J CLIN EPIDEMIOL 50;9:1003-1009, 1997. 
0 1997 Elsevier Science Inc. 
KEY WORDS. Cardiovascular risk factors, impaired glucose tolerance, insulin resistance, non-insulin- 
dependent diabetes mellitus, proinsulin 
INTRODUCTION 
Since the World Health Organization (WHO) defined im- 
paired glucose tolerance [l-3], there have been several 
cross-sectional and prospective studies published on the 
prevalence of cardiovascular risk factors among people with 
impaired glucose tolerance and with newly diagnosed non- 
insulin-dependent diabetes mellitus (NIDDM) [d-12]. 
Both in cross-sectional studies and in prospective studies 
increasing levels of cardiovascular risk factors with decreas- 
ing glucose tolerance have been found. Furthermore, people 
with impaired glucose tolerance turn out to be at substantial 
risk of developing cardio- and cerebrovascular diseases: the 
mortality due to these causes is approximately 2-fold com- 
pared with people with normal glucose tolerance [13-151. 
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The joint presence of unfavorable levels of the various car- 
diovascular risk factors, including hypertension, high tri- 
glyceride levels, and low HDL-cholesterol levels, is con- 
sidered to reflect insulin resistance. This clustering has 
been labeled as Syndrome X or insulin resistance syndrome 
[16-211. 
Saad et al. [22] hypothesized a two-step model for the 
development of diabetes in Pima Indians. The first step, the 
transition from normal to impaired glucose tolerance, would 
depend mainly on the presence of insulin resistance. The 
second step, worsening from impaired glucose tolerance to 
diabetes, although accompanied by some further worsening 
of insulin resistance, is assumed to be primarily dependent 
on the development of beta-cell dysfunction. It is unclear 
if this is also the case in a Caucasian population. We previ- 
ously reported the associations of the measurements of the 
glucose metabolism, including insulin and proinsulin levels, 
with the conversion to NIDDM in people with impaired 
glucose tolerance after 15 months of follow-up [23]. The 
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fasting proinsulin level predicted the conversion to NIDDM 
suggesting that beta-cell dysfunction, rather than insulin re- 
sistance, plays a more important role in the future develop- 
ment of NIDDM in an impaired glucose intolerant Cauca- 
sian population. In this study the cardiovascular risk factors, 
as major components of the insulin resistance syndrome, are 
analyzed as potential predictors of the conversion to 
NIDDM and normal glucose tolerance. To study a well- 
defined impaired glucose tolerant category, people were 
classified on the basis of the mean value of two oral glucose 
tolerance tests. Previous studies, which reported the inci- 
dence of NIDDM in Caucasian populations, the category 
of impaired glucose tolerance has been defined on the basis 
of one oral glucose tolerance test only [9-l 11. Furthermore, 
in those studies specific insulin and proinsulin were not 
measured and not all the determinants of the lipid metabo- 
lism were analyzed. 
The aims of the present study were to assess the incidence 
of NIDDM and to analyze the various cardiovascular risk 
factors at baseline as predictors of the conversion to 
NIDDM and to normal glucose tolerance. 
SUBJECTS AND METHODS 
Subjects 
From October 1989 to December 1991 a cross-sectional sur- 
vey of glucose tolerance was conducted. People aged 50- 
74 years were randomly selected from the computerized reg- 
istry of the mid-sized town of Hoorn in The Netherlands, 
which has approximately 59,000 (mixed rural and urban) 
inhabitants. 
Oral @ucose Tolerance Tests 
Based on the mean values of two paired oral glucose toler- 
ance tests, which were performed 2-6 weeks apart, persons 
were classified in categories of glucose tolerance according 
to the WHO criteria, as described in detail previously [24]. 
Samples were taken at fasting (between 8.30 and 9.30 am 
after a lo-hour fast), and 120 minutes after a 75-gram gluy 
case load. Additional blood samples were taken for the mea- 
surements of fasting and 2-hour specific insulin, and fasting 
and 2-hour proinsulin levels. Height, weight, and waist and 
hip circumference were measured in a standardized way. 
Follow-Up Visits 
Of the persons with impaired glucose tolerance (n = 224) 
invited to participate in the present study 70% (n = 158) 
accepted. The baseline characteristics from non-partici- 
pants in the study did not differ from the participating peo- 
ple. In a non-parametric Mann-Whitney test no statistically 
significant difference was found. At 13-18-month intervals, 
people underwent a repeated oral glucose tolerance test, 
separated by two weeks. This paper reports the results of two 
follow-up measurements. People with NIDDM according to 
the WHO criteria were referred to the general practitioner. 
In the case of conversion to NIDDM at the first follow-up 
visit only the results of the first follow-up visit were ana- 
lyzed. All persons with no conversion to NIDDM partici- 
pated in the second follow-up visit. 
Baseline Measurements 
Body mass index (BMI) was calculated as weight (in kilo- 
grams) divided by height (in meters squared), waist to hip 
ratio (W/H ratio) were taken, according to a standardized 
procedure [25], as the horizontal circumference halfway be- 
tween the lower rib margin and the iliac crest, and the point 
of the maximum circumference over the buttocks, respec- 
tively. The W/H ratio was defined as waist circumference 
divided by hip circumference. Blood pressure was measured 
on the right arm of each seated person, after at least five 
minutes rest, with a random zero mercury sphygmomanome- 
ter (Hawksley-Gelman). The average of two readings of sys- 
tolic and diastolic blood pressure (Korotkoff V) to the near- 
est even digit was recorded. Fasting serum cholesterol and 
HDL-cholesterol were measured with the enzymatic calori- 
metric method (CHOD-PAP, Boehringer Mannheim), fast- 
ing serum triglyceride with the enzymatic calorimetric 
method (CPO-PAP, Boehringer Mannheim). Fasting and 
2-hour plasma glucose levels, 2-6 weeks apart, were mea- 
sured with a glucose dehydrogenase method using the 
Granu-test (Merck). The inter-assay coefficient of variation 
was 1.4%. Fasting and 2-hr plasma specific insulin levels 
were measured using double-antibody radio-immunoassay 
(lot SP2 1, Linco Research, St Louis, MO) in which proinsu- 
lin and 32/33 splitproinsulin cross-reacts by ~0.2%. The 
inter-assay coefficient of variation was 6% in the range 
of 40-1000 pmol/l. The lower limit of sensitivity was 12 
pmol/l. Plasma proinsulin level was measured by a double- 
antibody radioimmunoassay based on reagents from Dr. 
R. R. Bowsher (Lilly Laboratory for Clinical Research, Indi- 
anapolis, IN) as previously described [24]. In this assay, des 
31,32-proinsulin cross-reacts by 63%. The inter-assay coef- 
ficient of variation was 6% at levels of 100 pmol/l and in- 
creased to 15% at lower levels. The lower limit of detection 
was 3 pmol/l. All the characteristics of the assays were de- 
rived at our laboratory of the Department of Endocrinology. 
Data Analyses 
Based on the mean values of two paired oral glucose toler- 
ance tests, which were performed two weeks apart, persons 
were classified in categories of glucose tolerance according 
to the WHO criteria (mean 2-hr post-load plasma glucose 
level greater than 11.1 mmol/l). Because of the variable 
follow-up time, both the incidence density-the number of 
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cases devided by the observed time at risk-and the cumu- 
lative incidence for the conversion to NIDDM were calcu- 
lated. The 95% confidence interval was calculated using the 
method described by Miettinen [26]. The baseline charac- 
teristics of non-converters, converters to normal glucose 
tolerance, and converters to NIDDM are depicted with 
their medians and the corresponding 20th and 80th percen- 
tiles. The plasma glucose values and the specific insulin val- 
ues are the average of two measurements of the paired oral 
glucose tolerance test. For analyzing the crude relative risk 
for conversion to NIDDM the cardiovascular risk factors 
were dichotomized [27,28]. As cut-off point for hyper- 
cholesterolaemia a level > 6.2 was used and for hypertri- 
glyceridemia level > 2.2 mmol/l. Because mean HDL- 
cholesterol levels are approximately 0.3 mmol/l higher 
in women, different cut-off points were chosen for the defi- 
nition of abnormal HDL-cholesterol levels in men and 
women: < 0.9 and < 1.2 mmol/l, respectively. Hyperten- 
sion was defined by diastolic BP > 95 and/or systolic BP > 
160 mmHg, or current use of antihypertensive medication 
[28]. The chi-squared test was used for evaluating the null 
hypothesis that conversion to NIDDM and a high cardio- 
vascular risk factor were independent. To analyze potential 
predictors of the incidence of conversion to NIDDM on the 
one hand, and conversion to normal glucose tolerance on 
the other hand, two backward stepwise multiple logistic re- 
gression analyses were used with age, sex, and months of 
follow-up as potential confouders and the other indepen- 
dent variables (the cardiovascular risk factors at baseline, 
the specific insulin levels and anthropometric measure- 
ments) entered stepwise into the equation. As reference cat- 
egory non-converters and converters in the opposite direc- 
tion was used. A p-value of 0.05 was used as the criterion 
for entry at each step. Different interaction terms were en- 
tered, as were the ratio between triglyceride level and HDL- 
cholesterol level. After the backward procedure procedure, 
a forward procedure was used. All statistical analyses were 
performed with the SPSS-PC 5.0 statistical package [29]. 
RESULTS 
The mean follow-up time was 36 months (range 13-55 
months). The cumulative incidence of NIDDM was 34% 
(95% CI 16.9-45.1). The incidence density was O.lZ/year 
(95% CI 0.02-0.22). Table 1 presents the differences be- 
tween participants and non-participants. In a non-para- 
metrische Wilcoxon test none of the differences between 
participants and non-participants were significant. 
Table 2 presents the baseline characteristics for the non- 
converters, converters to normal glucose tolerance or to 
NIDDM and for all people. 
Figure 1 presents the prevalence rates of high cardiovas- 
cular risk factors at baseline in the three categories of glu- 
cose tolerance at the end of follow-up. As can be seen from 
the figure about 70% of the subjects with impaired glucose 
tolerance have a high cholesterol level at baseline, 28.5% 
a high triglyceride level, about 30% a low HDL-cholesterol 
and finally about 45% a high blood pressure at baseline. 
Table 3 presents the unadjusted relative risk of a high 
cardiovascular risk factors dichotomized as described in the 
method paragraph, for the incidence of conversion to 
NIDDM and the results of chi-squared analyses. No statisti- 
cally significant associations of the cardiovascular risk fac- 
tors with the incidence of conversion to NIDDM were 
present. In a separate model, where the ratio triglyceride/ 
HDL-cholesterol was used instead of triglyceride and HDL 
cholesterol, no significant associations were found with the 
incidence of NIDDM. 
Table 4 presents the result of a multiple logistic regression 
analyses with the conversion to NIDDM as the dependent 
TABLE 1. Differences between participants and nomparticipants in the study 
Participants Nowparticipants 
(percentile) (percentile) 





Body Mass Index 
Waist/Hip ratio 
Fasting plasma glucose (mmol/l) 
2-hour plasma glucose (mmol/l) 
Fasting spec. insulin (pmol/l) 
2-hour insulin (pmol/l) spec. 
Cholesterol (mmol/l) 




65.4 59.7 70.3 66.6 60 70.7 
27.7 25.4 30 27.4 25.3 30 
0.93 0.85 0.99 0.93 0.87 0.97 
6 5.6 6.4 5.7 5.4 6.1 
8.9 
7::; 
9.6 8 7.4 9.7 
95.7 125.6 82.3 62.8 136.6 
589.8 408.8 887.3 518.6 326.6 876.6 
6.9 6 7.4 6.5 5.8 7.3 
1.2 0.99 1.46 1.2 1.01 1.43 
1.7 1.3 2.4 1.6 1.2 2.2 
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TABLE 2. Baseline characteristics of non-converters and converters to normal glucose tolerance, non-insulin diabetes mellitus 
(NIDDM), and the total cohort 
Non-converters 
n = 67 
Converters to 
NIDDM 
n = 56 
Converters to 
NGT 
n = 35 
Total 
n = 158 
Age (year) 
Months follow-u1, 
Percentage n& (%) 








Fasting plasma glucose (mrnol/l) 
2-hour plasina glucose (mmol/l) 
Fasting specific insulin (pmol/l) 










0.96 (0.94-1.0) 0.98 (0.9-1.01) 




























































“Median (20-80 puccntilcs) 
variable. The model presents the best fit after entering step- 
wise the independent variables into the regression equation, 
with age, sex and months of follow-up entered first as poten- 
tial confounders. Other independent variables were BMI, 
W/H ratio, HbA,,, 2-hr glucose level, fasting and 2-hr spe- 
cific insulin level, and fasting and 2-hr proinsulin level. 
About the same significant associations were found for the 
2-hr glucose level and fasting proinsulin level as earlier de- 
scribed after 24 months of follow-up [23]. 
Table 5 presents the results of two multiple logistic regres- 
sion analyses. In the first model the conversion of NIDDM 
is used as the dependent variable. In the second model the 
conversion to normal glucose tolerance is used as the depen- 
dent variable. Both models present the best fit after entering 
FIGURE 1. Percentage of a 
high level of each cardiovas- 
cular risk factor at baseline in 
the three categories of glucose 
tolerance category at follow- 
up* 
high BP HDL-c triglyceride cholesterol 
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TABLE 3. The relative risk conferred by the presence of catgorised cardiovascular risk 
factor for the incidence of NIDDM 
Relative risk NIDDM 
(95% CI) Chi square p-value 
Cholesterol > 6.1 mmol/l 
Low HDL-cholesterol (mmol/l) 
Female 
Male 
High triglyceride (mmol/l) 
Hypertension (WHO-criterion) 
1.03 (0.64-1.64) 0.01 0.91 
1.60 (0.86-2.98) 2.2 0.14 
1.29 (0.71-2.33) 0.63 0.43 
1.42 (0.93-2.26) 2.5 0.11 
1.06 (0.69-1.64) 0.78 0.78 
TABLE 4. Multiple logistic regression analysis with conversion to NIDDM as dependent 
variable 
Variable Odds ratio 
95% confidence 
interval p-Value 
Age ( 1 -year difference) 
Sex (female/male) 
2,hour plasma glucose (1 mmol/l difference) 
Fasting proinsulin (10 pmol difference) 
1.06 0.36-3.08 0.29 
0.48 0.18-1.31 0.97 
3.56 1.84-6.89 <O.Ol 
2.1 1.02-4.3 0.04 
Variables not in equation: BMI, W/H ratio, HI&, fasting, and 2-hour glucose lcvcl, fasting and 2-hour specific 
insulin level, fasting and 2-hour proinsulin Icvcl, hypertension (WHO criterion), and the product-term of sex 
and W/H ratio. 
TABLE 5. Multiple logistic regression analysis with conversion to NIDDM as dependent 





Odds ratio interval p-Value 
Model 1: dependent variable: conversion to NIDDM 
Variables in the equation 
Age (1 year difference) 
Sex (f/m) 
Months follow-up (1 month) 
Variables not in the equation 
Triglyceride, HDL-cholesterol, fasting and 
2-hour specific insulin level, hypertension 
(WHO criterion), W/H ratio 
1.05 0.99-1.11 0.07 
0.49 0.23-1.09 0.08 
0.94 0.90-0.98 0.04 
Model 2: dependent variable: conversion to NGT 
Variables in the equation 
Age (1 year difference) 
Sex (f/m) 
Months follow-up (1 month) 
HDL-cholesterol (1 mmol/l difference) 
Variables not in the equation 
Triglyceride, fasting and 2-hour specific insulin 
level, hypertension (WHO criterion), W/H 
ratio 
0.94 0.88-0.99 0.04 
1.95 0.71-5.32 0.2 
1.03 0.98-1.08 0.19 
1.58 1.17-20.4 0.03 
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stepwise the independent variables into the regression equa- 
tion, with age, sex, and months of follow-up entered first 
as potential confounders. Other independent variables were 
W/H ratio, hypertension (WHO criterion), the fasting in- 
sulin level, the triglyceride level, the cholesterol level, and 
the HDL-cholesterol level as the independent variables. 
Transformation of the skewed distributed variables and in- 
teraction terms did not improve the fit of the models. No 
statistically significant association of the various cardiovas- 
cular risk factors with the incidence of NIDDM was found. 
In both the stepwise foreward analyses and the stepwise 
backward analyses, a statistically significant association was 
found between the HDL-cholesterol level and the conver- 
sion to normal glucose tolerance. 
DISCUSSION 
The cumulative incidence of NIDDM over an average pe- 
riod of three years was 34%, which is clearly higher than 
in similar studies among other Caucasian populations [lo- 
121. The major reason for this might be the use of more 
stringent and precise criteria for both impaired glucose tol- 
erance and NIDDM, as the mean value of two oral glucose 
tolerance tests was used for qualification. It has been pro- 
posed that low HDL cholesterol and high serum triglyceride 
levels may be due to reduced insulin sensitivity. In combina- 
tion with hypertension, hyperinsulinaemia, and glucose in- 
tolerance, it constitutes Reaven’s “Syndrome X” or the in- 
sulin resistance syndrome [15-201. In the two step model 
hypothesis for the development of NIDDM, the first step 
from normal glucose tolerance to impaired glucose tolerance 
would be predominantly determined by insulin resistance. 
Manifestations of insulin resistance are high fasting and 
post-load insulin levels, high triglycerides and low HDL- 
cholesterol levels, and a high W/H ratio [30-321. In the 
cross-sectional part of the Hoorn Study, as in other studies, 
high fasting and high post-load insulinemia identified sub- 
jects with dyslipidemia and hypertension [33-351; more- 
over, subjects with impaired glucose tolerance and NIDDM 
have a 2-4 times higher risk for dyslipidaemia and hyper- 
tension than subjects with normal glucose tolerance. The 
second step, the transition from impaired glucose tolerance 
to NIDDM would be predominantly determined by beta- 
cell dysfunction accompanied with some further worsening 
of insulin resistance. A high fasting proinsulin level [36,37] 
and a high proinsulin to insulin ratio [38,39] have been used 
as measures of beta-cell dysfunction. Recent studies have 
reported that the insulin secretory capacity is impaired in 
impaired glucose tolerance [40-451. As also reported after 
one follow-up measurement, the fasting proinsulin level, 
apart from the 2-hr plasma glucose level, predicts the con- 
version to NIDDM in people with impaired glucose toler- 
ance, suggesting beta-cell dysfunction [22]. The HDL- 
cholesterol, the triglyceride levels and the insulin levels, as 
components of the insulin resistance syndrome, do not pre- 
diet the conversion from impaired glucose tolerance to 
NIDDM. However high HDL cholesterol levels predict the 
conversion from impaired glucose tolerance to normal glu- 
cose tolerance, suggesting a role for insulin sensitivity, here 
some study limitations have to be mentioned. The interpre- 
tation of the fasting proinsulin level as a reflection of beta- 
cell function is a potential problem. The assay used in our 
study was not able to differentiate between intact proinsulin 
and des 31-32 proinsulin. The inhibition of the conversion 
from des 31-32 proinsulin to insulin by hyperglycemia, may 
therefore have overestimated the contribution of beta-cell 
dysfLmction as reflected by the high proinsulin levels found 
in our study. The fact that high HDL cholesterol predicts 
the conversion from impaired glucose tolerance to normal 
glucose tolerance is probably a reflection of a more healthy 
lifestyle behavior; moreover, we did not study the conver- 
sion from normal glucose tolerance to impaired glucose tol- 
erance. For that reason we have planned a prospective study 
in subjects with normal glucose tolerance to study the rela- 
tive contribution of beta-cell dysfunction for the conversion 
from normal glucose tolerance to impaired glucose toler- 
ance. In summary, in Caucasian people with well-defined 
impaired glucose tolerance, the cumulative incidence of 
NIDDM is high and our results are in line with the hypothe- 
sis of the two-step model of the development of NIDDM. 
This study was supported by the “Diabetes Fonds Ned&and.” We 
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